Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
11
CCCC Quote, Financials, Valuation and Earnings
Last price:
$2.02
Seasonality move
:
-24.32%
Day range:
$2.02 - $2.13
52-week range:
$1.09 - $4.26
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.77x
P/B ratio:
1.26x
Volume:
1M
Avg. volume:
1.8M
1-year change:
-47.09%
Market cap:
$195.3M
Revenue:
$35.6M
EPS (TTM):
-$1.67
Analysts' Opinion
-
Consensus RatingC4 Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $11.14, C4 Therapeutics, Inc. has an estimated upside of 433.15% from its current price of $2.09.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $2.09.
Fair Value
-
According to the consensus of 7 analysts, C4 Therapeutics, Inc. has 433.15% upside to fair value with a price target of $11.14 per share.
CCCC vs. S&P 500
-
Over the past 5 trading days, C4 Therapeutics, Inc. has underperformed the S&P 500 by -15.67% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
C4 Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
C4 Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter C4 Therapeutics, Inc. reported revenues of $11.2M.
Earnings Growth
-
C4 Therapeutics, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter C4 Therapeutics, Inc. reported earnings per share of -$0.44.
Enterprise value:
72.1M
EV / Invested capital:
0.33x
Price / LTM sales:
4.77x
EV / EBIT:
--
EV / Revenue:
2.40x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.76x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$22.2M
Return On Assets:
-37.05%
Net Income Margin (TTM):
-395.51%
Return On Equity:
-60.62%
Return On Invested Capital:
-45.67%
Operating Margin:
-210.86%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $20.3M | $33.7M | $30.1M | $15.4M | $11.2M | |
| Gross Profit | $12.3M | $25.8M | $22.2M | $13.3M | $9.2M | |
| Operating Income | -$139.9M | -$116.9M | -$119.1M | -$28.2M | -$23.7M | |
| EBITDA | -$131.8M | -$109.1M | -$111.1M | -$26.2M | -$21.6M | |
| Diluted EPS | -$2.75 | -$1.70 | -$1.67 | -$0.35 | -$0.44 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $412.3M | $325.5M | $223.7M | $273.2M | $206.9M | |
| Total Assets | $507.9M | $461.4M | $333M | $376.1M | $265.5M | |
| Current Liabilities | $48.7M | $45.3M | $30.3M | $43.3M | $35.9M | |
| Total Liabilities | $109.1M | $143.3M | $117M | $133.4M | $111.1M | |
| Total Equity | $398.8M | $318.2M | $216M | $242.7M | $154.4M | |
| Total Debt | $22.7M | $83.5M | $67.1M | $61.5M | $55.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$112M | -$71.2M | -$94.5M | -$24.1M | -$31.2M | |
| Cash From Investing | $135.7M | -$33M | $85.8M | $162K | $4.1M | |
| Cash From Financing | -$12.1M | $102.9M | $7.8M | $10.5M | $7.8M | |
| Free Cash Flow | -$115M | -$71.6M | -$95.1M | -$24.1M | -$31.6M | |
CCCC
Sector
Market Cap
$195.3M
$28.4M
Price % of 52-Week High
47.3%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-3.75%
-1.49%
1-Year Price Total Return
-47.09%
-16.67%
Beta (5-Year)
2.874
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$2.24
200-day SMA
Buy
Level
$2.08
Bollinger Bands (100)
Sell
Level
2.2 - 2.76
Chaikin Money Flow
Sell
Level
-24.4M
20-day SMA
Sell
Level
$2.45
Relative Strength Index (RSI14)
Sell
Level
37.64
ADX Line
Sell
Level
18.12
Williams %R
Buy
Level
-88.7574
50-day SMA
Sell
Level
$2.43
MACD (12, 26)
Sell
Level
-0.10
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-13.4M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.6705)
Sell
CA Score
(Annual)
Level (-1.2559)
Buy
Beneish M-Score
(Annual)
Level (-3.1975)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (1.6735)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, CCCC has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The CCCC average analyst price target in the past 3 months is $11.14.
-
Where Will C4 Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that C4 Therapeutics, Inc. share price will rise to $11.14 per share over the next 12 months.
-
What Do Analysts Say About C4 Therapeutics, Inc.?
Analysts are divided on their view about C4 Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that C4 Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is C4 Therapeutics, Inc.'s Price Target?
The price target for C4 Therapeutics, Inc. over the next 1-year time period is forecast to be $11.14 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is CCCC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for C4 Therapeutics, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of CCCC?
You can purchase shares of C4 Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase C4 Therapeutics, Inc. shares.
-
What Is The C4 Therapeutics, Inc. Share Price Today?
C4 Therapeutics, Inc. was last trading at $2.02 per share. This represents the most recent stock quote for C4 Therapeutics, Inc.. Yesterday, C4 Therapeutics, Inc. closed at $2.09 per share.
-
How To Buy C4 Therapeutics, Inc. Stock Online?
In order to purchase C4 Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CCCC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CCCC
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.26x
1.81x
Price / LTM sales
4.77x
1.58x
Growth Metrics
CCCC
Sector
Revenue growth
-26.9%
4.62%
Earnings growth
-25.12%
10.7%
Revenue (5-year growth)
10.73%
6.5%
Earnings forecast
-$0.39
-$0.21
Profitability
CCCC
Sector
Profitability FY 2024
$27.7M
$3.6M
Return on invested capital
-45.67%
-31.84%
Return on assets
-37.05%
-27.96%
Return on equity
-60.62%
-37.63%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Feb
26
Estimated Next Earnings Date
Feb
5
Balance Sheet
CCCC
Sector
Total cash
$191.9M
$26.4M
Short term investments
$189.4M
$25.7M
Total assets
$349.6M
$76.9M
Long term debt
$55.2M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 24
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
